Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,509.01 +33.92 (+0.62%) Dow
39,331.85 +162.33 (+0.41%) Nasdaq
18,028.76 +149.46 (+0.84%) Bitcoin USD
60,537.68 -2,031.34 (-3.25%) CMC Crypto 200
1,305.05 -29.87 (-2.24%)
LBPH Aug 2024 25.000 call
- Zacks
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
- Business Wire
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
LA JOLLA, Calif., July 01, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older.
- Business Wire
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif., June 10, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.
